Clinical trial
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced…
NCT00413283 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00413283 |
|---|---|
| Title | Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia |
| Intervention type | Biological, Drug |
| Interventions | Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin |
| Enrollment | 63 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Dec 19, 2006 |
| Last update posted | Oct 24, 2013 |
| Countries | Austria, Canada, Germany, Hungary, Ireland, Italy, Portugal, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: